Serum CD44 levels in patients with non-small cell lung cancer and their relationship with clinicopathological features

Lung Cancer

Volumn 18, Issue 2, 1997, Pages 147-157

  Takigawa, Nagio ^a   Segawa, Yoshihiko ^a   Mandai, Koichi ^a   Takata, Ichiro ^a   Fujimoto, Nobukazu ^a  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

CD44; Cell adhesion molecules; Enzyme linked immunosorbent assay; Immunohistochemistry; Non small cell lung cancer; Tumor marker

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; PRIORITY JOURNAL; TRANSBRONCHIAL BIOPSY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; BIOPSY; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG DISEASES; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; VARIATION (GENETICS);

EID: 0030921236     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)00060-3     Document Type: Article

References (27)

1. Ariza A, Mate JL, Isamat M, López D, von Uexküll-Güldeband C, Rosell R, Fernández-Vasalo A, Navas-Palacios JJ. Standard and variant CD44 isoforms are commonly expressed in lung cancer of the non-small cell type but not of the small cell type. J Pathol 1995;177:363-8.
2. Cannistra SA, Abu-Jawdeh G, Niloff J, Strobel T, Swanson L, Anderson J, Offensmeier C. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J Clin Oncol 1995;13:1912-21.
3. Dall P, Heider K-H, Sinn H-P, Skroch-Angel P, Adolf G, Kaufmann M, Herrlich P, Ponta H. Comparison of immunochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 1995;60:471-7.
4. Friedrichs K, Franke F, Lisboa B-W, Kügler G, Gille I, Terpe H-J, Hölzel F, Maass H, Günthert U. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995;55:5424-33.
5. Guo Y-J, Liu G, Wang X, Jin D, Wu M, Ma J, Sy M-S. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 1994;54:422-6.
6. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haubmann I, Matzku S, Wenzel A, Ponta H, Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
7. Haynes BF, Telen MJ, Hale LP, Denning SM. CD44-molecule involved in leukocyte adherence and T-cell activation. Immunol Today 1989;10:423-8.
8. Hofmann M, Rudy W, Zöler M, Tölg C, Ponta H, Herrlich P, Günthert U. CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 1991;51:5292-7.
9. Jackson DG, Schenker T, Waibel R, Bell JI, Stahel RA. Expression of alternatively spliced forms of the CD44 extracellular-matrix receptor on human lung carcinomas. Int J Cancer 1994;Suppl 8:110-5.
10. Joensuu H, Ristamäki R, Klemi PJ, Jalkanen S. Lymphocyte homing receptor (CD44) expression is associated with poor prognosis in gastrointestinal lymphoma. Br J Cancer 1993;68:428-32.
11. Jung K, Lein M, Weiss S, Schnorr D, Henke W, Loening S. Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia. Eur J Cancer 1996;32A:627-30.
12. Kainz C, Kohlberger P, Sliutz G, Tempfer C, Heinzl H, Reinthaller A, Breitenecker G, Koelbl H. Splice variants of CD44 in human cervical cancer Stage IB to IIB. Gynecol Oncol 1995;57:383-7.
13. Kainz C, Tempfer C, Winkler S, Sliutz G, Koelbl H, Reinthaller A. Serum CD44 splice variants in cervical cancer patients. Cancer Lett 1995;90:231-4.
14. Kan M, Kanayama H, Naruo S, Tsuji M, Kojima K, Kurokawa Y, Kagawa S. Serological evaluation of soluble CD44 in renal cancer. Jpn J Cancer Res 1996;87:1191-4.
15. Kaufmann M, Heider K-H, Sinn H-P, von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995;345:615-9.
16. Mackay CR, Terpe H-J, Stauder R, Marston WL, Stark H, Günthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994;124:71-82.
17. Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992;340:1053-8.
18. Maeda Y, Segawa Y, Takigawa N, Takata I, Fujimoto N. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer. Internal Med 1996;35:764-71.
19. Mountain CF. A new international staging system for lung cancer. Chest 1986;Suppl 89:225-33.
20. Mulder J-WR, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, Offerhaus GJA, Pals ST. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994;344:1470-2.
21. Penno MB, August JT, Baylin SB, Mabry M, Linnoila RI, Lee VS, Croteau D, Yang XL, Rosada C. Expression of CD44 in human lung tumors. Cancer Res 1994;54:1381-7.
22. Ristamäki R, Joensuu H, Salmi M, Jalkanen S. Serum CD44 in malignant lymphoma: an association with treatment response. Blood 1994;84:238-43.
23. Roye GD, Myers RB, Brown D, Poczatek R, Beenken SW, Grizzle WE. CD44 expression in dysplastic epithelium and squamous-cell carcinoma of the esophagus. Int J Cancer (Pred Oncol) 1996;69:254-8.
24. Sliutz G, Tempfer C, Winkler S, Kohlberger P, Reinthaller A, Kainz C. Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br J Cancer 1995;72:1494-7.
25. Speiser P, Wanner C, Tempfer C, Mittelböck M, Hanzal E, Bancher-Todesca D, Gitsch G, Reinthaller A, Kainz C. CD44 is an independent prognostic factor in early-Stage cervical cancer. Int J Cancer (Pred Oncol) 1997;74:185-8.
26. Tempfer C, Girsch G, Haesler G, Reinthaller A, Koelbl H, Kainz C. Prognostic value of immunohistochemically detected CD44 expression in patients with carcinoma of the vulva. Cancer 1996;78:273-7.
27. Yamaguchi A, Urano T, Goi T, Saito M, Takeuchi K, Hirose K, Nakagawara G, Shiku H, Furusawa K. Expression of CD44 variant containing exons 8 to 10 is a useful factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol 1996;14:1122-7.